FDA Refuses to File Moderna’s mRNA Influenza Vaccine (mRNA-1010)

Key Data at a Glance

The Comparator Dispute: Anatomy of the RTF

The core regulatory question is whether Moderna’s use of a licensed standard-dose influenza vaccine (Fluarix) as the active comparator in the pivotal Phase 3 efficacy trial constitutes an “adequate and well-controlled” study under 21 CFR §314.126. CBER’s position, articulated in Prasad’s RTF letter, is that it does not — because the comparator should have been a high-dose or adjuvanted flu vaccine (e.g., Fluzone HD, Fluad, Flublok), which are preferentially recommended by the CDC’s ACIP for adults ≥65.

Moderna’s counterargument is multi-layered and well-documented: During an April 2024 pre-Phase 3 consultation, CBER stated in writing that using a licensed standard-dose influenza vaccine would be “acceptable,” while recommending — but not requiring — the use of vaccines preferentially recommended for adults ≥65. CBER did not place a clinical hold or raise objections before enrollment began in September 2024. Furthermore, neither FDA regulations (21 CFR §314.126) nor FDA guidance on seasonal influenza vaccines explicitly require a “best-available standard of care” comparator.

An HHS spokesperson stated on February 11 that Moderna “exposed participants age 65 and over to increased risk of severe illness by giving them a substandard of care,” framing this as a patient safety issue. This rhetorical pivot is notable: the RTF letter itself did not cite safety concerns, and Moderna’s separate immunogenicity study in the ≥65 population showed superiority over a high-dose comparator.

Internal FDA Dissent: The Prasad Override

Multiple sources (STAT, CNN, Endpoints News) confirm the following chain of events:

• The career vaccine review team within CBER’s Office of Vaccines Research and Review (OVRR) was prepared to accept Moderna’s application for full review.
• OVRR Director David Kaslow, M.D., wrote a detailed internal memo supporting the review.
• Kaslow declined to sign the RTF letter.
• Prasad personally signed the RTF — a procedural departure, as RTFs are typically signed by the sub-office director overseeing the relevant therapeutic area, not the CBER center director.

This is consistent with Prasad’s pattern of overruling career FDA scientists since his appointment as CBER Director on May 6, 2025 (he briefly departed in late July 2025 and was reinstated August 9 at Makary’s request). Previous documented overrides include narrowing the pediatric label for Moderna’s Spikevax (COVID-19) and restricting COVID-19 vaccine approvals for Novavax to high-risk populations only.

Cascade Effects on Moderna’s Pipeline and Financials

mRNA-1083 (Flu/COVID Combination Vaccine)

The standalone flu vaccine (mRNA-1010) is the foundation for Moderna’s combination flu/COVID shot (mRNA-1083), which the company positions as a key revenue driver for 2027–2028. Moderna withdrew its initial mRNA-1083 BLA in May 2025 after the FDA requested additional Phase 3 influenza efficacy data. The company’s stated strategy was to refile mRNA-1083 after mRNA-1010 approval. With mRNA-1010 now in regulatory limbo, Jefferies notes that the path forward for mRNA-1083 is uncertain. Citi estimates the two products combined for ~$750M in projected 2028 revenue; those projections are now materially at risk.

2028 Cash Breakeven Target

Moderna’s stated goal of reaching cash breakeven by 2028 depends heavily on seasonal respiratory vaccine revenue. Citi analysts note that the RTF “throws a wrench into the company’s reliance on seasonal vaccines to reach its 2028 cash breakeven goal.” Leerink goes further, stating that the RTF “imperils” the 2028 breakeven guidance entirely. With Moderna burning through its ~$8B cash reserve, the timeline to profitability has lengthened.

Remaining Catalysts

• Oncology (mRNA-4157/V940): Five-year data with Merck showed 49% reduction in melanoma recurrence/death (announced January 20, 2026). Phase 3 readout expected H2 2026. This is now Moderna’s most important near-term catalyst.
• Ex-US Flu Approvals: EMA, Health Canada, and TGA have accepted the same application the FDA rejected. If mRNA-1010 is approved ex-US, it creates a regulatory divergence that highlights the idiosyncratic nature of the US risk.
• Q4 2025 Earnings (Feb 13): Management commentary on the RTF response strategy and Type A Meeting timeline will be the key focus.

Competitive Landscape: Sector-Wide Impact

The Broader Regulatory Pattern: Systematic Tightening

The mRNA-1010 RTF must be evaluated within the context of a consistent pattern of regulatory actions under current HHS/FDA leadership over the past 12 months:

• Capricor CRL (July 2025): Capricor Therapeutics received a surprise CRL for deramiocel (DMD cell therapy). Two senior FDA officials (Nicole Verdun, Rachael Anatol) were placed on administrative leave in June 2025, reportedly due to internal disagreements with Prasad over the Capricor file. Both subsequently left the agency.
• Replimune CRL (July 2025): Replimune received a surprise CRL for its melanoma drug RP1. Notably, this was driven primarily by CDER’s Richard Pazdur, who intervened in the CBER review, rather than Prasad directly. Replimune’s CEO stated that the issues in the CRL were not raised during mid- or late-cycle reviews.
• New Placebo Requirement (May 2025): HHS mandated placebo-controlled trials for all new vaccines. Flu vaccines were supposedly exempted — but the RTF’s insistence on a high-dose comparator effectively raises the evidentiary bar even within the exempted category.
• Streamlined Flu Pathway Eliminated: The FDA scrapped the accelerated pathway that previously allowed annual flu vaccine strain updates based on immunogenicity data alone, forcing full efficacy studies.
• CDC Schedule Changes (Jan 2026): The CDC unilaterally removed childhood immunization recommendations for flu and five other diseases. In December 2025, infant hepatitis B vaccination was deferred from birth to two months.
• mRNA Research Funding Canceled (Aug 2025): HHS canceled ~$500M in mRNA vaccine research contracts.
• COVID Vaccine Label Restrictions: Prasad personally narrowed pediatric Spikevax approval to high-risk children only, overruling reviewers who recommended broader access.

Investment Implications: Repricing CBER Regulatory Risk

For Portfolio Construction

The RTF introduces a new category of regulatory risk that must be modeled explicitly: the risk that prior FDA guidance on trial design is retroactively invalidated. This is distinct from typical binary approval risk and affects the entire CBER-regulated universe (vaccines, gene therapies, cell therapies, blood products).

• Increase discount rates on any program where regulatory approval depends on CBER under current leadership. TD Cowen notes the RTF “appears to deviate from historical review practices and seems unreasonably stringent.”
• Stress-test existing positions for comparator vulnerability. Any BLA or pre-BLA program that uses an active comparator (rather than placebo) and received trial design guidance from CBER before May 2025 is potentially exposed to retroactive standard-raising.
• Monitor CBER staffing closely. The departure of Verdun and Anatol, combined with Kaslow’s documented dissent, suggests institutional strain. Further senior departures from the vaccine review team would signal deeper dysfunction and longer review timelines.
• Evaluate geographic arbitrage. If mRNA-1010 is approved in the EU/Canada/Australia while blocked in the US, Moderna generates ex-US flu revenue while US competitors face no mRNA competition.

Catalysts to Monitor